{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:04:22Z","timestamp":1791594262249,"version":"4.3.4"},"reference-count":116,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"10","funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA018151"],"award-info":[{"award-number":["DA018151"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA041730"],"award-info":[{"award-number":["DA041730"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robertson Therapeutic Discovery Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2019,10,11]]},"abstract":"<jats:p>Two effective treatments for opioid addiction, methadone and buprenorphine-naloxone maintenance, should be widely implemented.<\/jats:p>","DOI":"10.1126\/sciadv.aax9140","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T19:19:14Z","timestamp":1570043954000},"source":"Crossref","is-referenced-by-count":102,"title":["Current status of opioid addiction treatment and related preclinical research"],"prefix":"10.1126","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-9091","authenticated-orcid":true,"given":"M. J.","family":"Kreek","sequence":"first","affiliation":[{"name":"Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Reed","sequence":"additional","affiliation":[{"name":"Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-0117","authenticated-orcid":true,"given":"E. R.","family":"Butelman","sequence":"additional","affiliation":[{"name":"Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017","volume":"67","author":"Scholl L.","year":"2019","unstructured":"L. Scholl, P. Seth, M. Kariisa, M. Wilson, G. Baldwin, Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017. MMWR Morb. Mortal. Wkly Rep. 67, 1419\u20131427 (2019).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"e_1_3_2_3_2","unstructured":"U.N.O.D.C. United Nations Office of Drugs and Crime (2017)."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/ALN.0b013e3181c38c25","article-title":"Incidence, reversal, and prevention of opioid-induced respiratory depression","volume":"112","author":"Dahan A.","year":"2010","unstructured":"A. Dahan, L. Aarts, T. W. Smith, Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 112, 226\u2013238 (2010).","journal-title":"Anesthesiology"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.conb.2004.05.005","article-title":"Mu opioid receptor: A gateway to drug addiction","volume":"14","author":"Contet C.","year":"2004","unstructured":"C. Contet, B. L. Kieffer, K. Befort, Mu opioid receptor: A gateway to drug addiction. Curr. Opin. Neurobiol. 14, 370\u2013378 (2004).","journal-title":"Curr. Opin. Neurobiol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.drugalcdep.2017.05.047","article-title":"Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances","volume":"178","author":"Kandel D. B.","year":"2017","unstructured":"D. B. Kandel, M. C. Hu, P. Griesler, M. Wall, Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances. Drug Alcohol Depend. 178, 501\u2013511 (2017).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jama.1989.03420070058030","article-title":"HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987","volume":"261","author":"Des Jarlais D. C.","year":"1989","unstructured":"D. C. Des Jarlais, S. R. Friedman, D. M. Novick, J. L. Sotheran, P. Thomas, S. R. Yancovitz, D. Mildvan, J. Weber, M. J. Kreek, R. Maslansky, HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA 261, 1008\u20131012 (1989).","journal-title":"JAMA"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.12.5391"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/y86-001","article-title":"The therapeutic use of heroin: A review of the pharmacological literature","volume":"64","author":"Sawynok J.","year":"1986","unstructured":"J. Sawynok, The therapeutic use of heroin: A review of the pharmacological literature. Can. J. Physiol. Pharmacol. 64, 1\u20136 (1986).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jpainsymman.2005.01.010","article-title":"Oxycodone","volume":"29","author":"Kalso E.","year":"2005","unstructured":"E. Kalso, Oxycodone. J. Pain Symptom Manage. 29, S47\u2013S56 (2005).","journal-title":"J. Pain Symptom Manage."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The promotion and marketing of oxycontin: Commercial triumph, public health tragedy","volume":"99","author":"Van Zee A.","year":"2009","unstructured":"A. Van Zee, The promotion and marketing of oxycontin: Commercial triumph, public health tragedy. Am. J. Public Health 99, 221\u2013227 (2009).","journal-title":"Am. J. Public Health"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7517-8-29","article-title":"Abuse risks and routes of administration of different prescription opioid compounds and formulations","volume":"8","author":"Butler S. F.","year":"2011","unstructured":"S. F. Butler, R. A. Black, T. A. Cassidy, T. M. Dailey, S. H. Budman, Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct. J. 8, 29 (2011).","journal-title":"Harm Reduct. J."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on \u03bc-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald M. K.","year":"2003","unstructured":"M. K. Greenwald, C. E. Johanson, D. E. Moody, J. H. Woods, M. R. Kilbourn, R. A. Koeppe, C. R. Schuster, J. K. Zubieta, Effects of buprenorphine maintenance dose on \u03bc-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28, 2000\u20132009 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_14_2","unstructured":"Drug Enforcement Administration 2018 National Drug Threat Assessment (2018); www.dea.gov\/sites\/default\/files\/2018-11\/DIR-032-18%202018%20NDTA%20final%20low%20resolution.pdf."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths \u2014 United States, 2000\u20132014","author":"Rudd R. A.","year":"2016","unstructured":"R. A. Rudd, N. Aleshire, J. E. Zibbell, R. A. Gladden, Increases in drug and opioid overdose deaths \u2014 United States, 2000\u20132014. Morb. Mortal. Wkly. Rep., 1378\u20131382 (2016).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"e0219717","DOI":"10.1371\/journal.pone.0219717","article-title":"Subtypes in patients with opioid misuse: A prognostic enrichment strategy using electronic health record data in hospitalized patients","volume":"14","author":"Afshar M.","year":"2019","unstructured":"M. Afshar, C. Joyce, D. Dligach, B. Sharma, R. Kania, M. Xie, K. Swope, E. Salisbury-Afshar, N. S. Karnik, Subtypes in patients with opioid misuse: A prognostic enrichment strategy using electronic health record data in hospitalized patients. PLOS ONE 14, e0219717 (2019).","journal-title":"PLOS ONE"},{"key":"e_1_3_2_17_2","unstructured":"Drug Enforcement Administration Fentanyl (2017); www.dea.gov\/sites\/default\/files\/sites\/getsmartaboutdrugs.com\/files\/publications\/DoA_2017Ed_Updated_6.16.17.pdf#page=40."},{"key":"e_1_3_2_18_2","unstructured":"Drug Enforcement Administration Fentanyl (2019); www.dea.gov\/factsheets\/fentanyl."},{"key":"e_1_3_2_19_2","first-page":"1","article-title":"Drug overdose deaths involving fentanyl, 2011\u20132016","volume":"68","author":"Spencer M. R.","year":"2019","unstructured":"M. R. Spencer, M. Warner, B. A. Bastian, J. P. Trinidad, Drug overdose deaths involving fentanyl, 2011\u20132016. Natl. Vital Stat. Rep. 68, 1\u201319 (2019).","journal-title":"Natl. Vital Stat. Rep."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1406143"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-med-011817-044739","article-title":"Use and misuse of opioids in chronic pain","volume":"69","author":"Volkow N.","year":"2017","unstructured":"N. Volkow, H. Benveniste, A. T. McLellan, Use and misuse of opioids in chronic pain. Annu. Rev. Med. 69, 451\u2013465 (2017).","journal-title":"Annu. Rev. Med."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1111\/add.13491","article-title":"Non-medical use of prescription opioids is associated with heroin initiation among US veterans: A prospective cohort study","volume":"111","author":"Banerjee G.","year":"2016","unstructured":"G. Banerjee, E. J. Edelman, D. T. Barry, W. C. Becker, M. Cerda, S. Crystal, J. R. Gaither, A. J. Gordon, K. S. Gordon, R. D. Kerns, S. S. Martins, D. A. Fiellin, B. D. Marshall, Non-medical use of prescription opioids is associated with heroin initiation among US veterans: A prospective cohort study. Addiction 111, 2021\u20132031 (2016).","journal-title":"Addiction"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15020262"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4088\/JCP.15m10386","article-title":"Nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder in the united states","volume":"77","author":"Saha T. D.","year":"2016","unstructured":"T. D. Saha, B. T. Kerridge, R. B. Goldstein, S. P. Chou, H. Zhang, J. Jung, R. P. Pickering, W. J. Ruan, S. M. Smith, B. Huang, D. S. Hasin, B. F. Grant, Nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder in the united states. J. Clin. Psychiatry 77, 772\u2013780 (2016).","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","article-title":"\u201cEvery \u2018never\u2019 I ever said came true\u201d: Transitions from opioid pills to heroin injecting","volume":"25","author":"Mars S. G.","year":"2014","unstructured":"S. G. Mars, P. Bourgois, G. Karandinos, F. Montero, D. Ciccarone, \u201cEvery \u2018never\u2019 I ever said came true\u201d: Transitions from opioid pills to heroin injecting. Int. J. Drug Policy 25, 257\u2013266 (2014).","journal-title":"Int. J. Drug Policy"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2012.12.027","article-title":"Prescription opioid mortality trends in New York City, 1990-2006: Examining the emergence of an epidemic","volume":"132","author":"Cerda M.","year":"2013","unstructured":"M. Cerda, Y. Ransome, K. M. Keyes, K. C. Koenen, M. Tracy, K. J. Tardiff, D. Vlahov, S. Galea, Prescription opioid mortality trends in New York City, 1990-2006: Examining the emergence of an epidemic. Drug Alcohol Depend. 132, 53\u201362 (2013).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_2_27_2","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2011-2016","volume":"67","author":"Hedegaard H.","year":"2018","unstructured":"H. Hedegaard, B. A. Bastian, J. P. Trinidad, M. Spencer, M. Warner, Drugs most frequently involved in drug overdose deaths: United States, 2011-2016. Natl. Vital. Stat. Rep. 67, 1\u201315 (2018).","journal-title":"Natl. Vital. Stat. Rep."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2013.280377","article-title":"Physician education in addiction medicine","volume":"310","author":"Wood E.","year":"2013","unstructured":"E. Wood, J. H. Samet, N. D. Volkow, Physician education in addiction medicine. JAMA 310, 1673\u20131674 (2013).","journal-title":"JAMA"},{"key":"e_1_3_2_29_2","unstructured":"Surgeon General Facing Addiction in America (2016); https:\/\/addiction.surgeongeneral.gov\/."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan J. R.","year":"2019","unstructured":"J. R. Morgan, B. R. Schackman, Z. M. Weinstein, A. Y. Walley, B. P. Linas, Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 200, 34\u201339 (2019).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2217\/pgs-2017-0092","article-title":"The \u03bc-opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment","volume":"18","author":"Levran O.","year":"2017","unstructured":"O. Levran, E. Peles, M. Randesi, J. C. da Rosa, M. Adelson, M. J. Kreek, The \u03bc-opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment. Pharmacogenomics 18, 1387\u20131391 (2017).","journal-title":"Pharmacogenomics"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cobeha.2016.12.002","article-title":"Endogenous opioid system in addiction and addiction-related behaviors","volume":"13","author":"Reed B.","year":"2017","unstructured":"B. Reed, E. R. Butelman, M. J. Kreek, Endogenous opioid system in addiction and addiction-related behaviors. Curr. Opin. Behav. Sci. 13, 196\u2013202 (2017).","journal-title":"Curr. Opin. Behav. Sci."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.drugalcdep.2013.02.036","article-title":"Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol","volume":"132","author":"Compton W. M.","year":"2013","unstructured":"W. M. Compton, D. A. Dawson, R. B. Goldstein, B. F. Grant, Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol. Drug Alcohol Depend. 132, 387\u2013390 (2013).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0143-4179(84)90081-7","article-title":"ACTH, cortisol and \u03b2-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans","volume":"5","author":"Kreek M. J.","year":"1984","unstructured":"M. J. Kreek, J. Ragunath, S. Plevy, D. Hamer, B. Schneider, N. Hartman, ACTH, cortisol and \u03b2-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5, 277\u2013278 (1984).","journal-title":"Neuropeptides"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00213-010-1966-9","article-title":"Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats","volume":"212","author":"Cooper Z. D.","year":"2010","unstructured":"Z. D. Cooper, Y. G. Shi, J. H. Woods, Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats. Psychopharmacology 212, 369\u2013378 (2010).","journal-title":"Psychopharmacology"},{"key":"e_1_3_2_36_2","first-page":"1128","article-title":"Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal","volume":"276","author":"Rosen M. I.","year":"1996","unstructured":"M. I. Rosen, T. J. McMahon, F. A. Hameedi, H. R. Pearsall, S. W. Woods, M. J. Kreek, T. R. Kosten, Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. J. Pharmacol. Exp. Ther. 276, 1128\u20131135 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.112.005942"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0006-8993(96)01125-0","article-title":"Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: Decrease in activity after chronic morphine treatment","volume":"746","author":"Selley D. E.","year":"1997","unstructured":"D. E. Selley, E. J. Nestler, C. S. Breivogel, S. R. Childers, Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: Decrease in activity after chronic morphine treatment. Brain Res. 746, 10\u201318 (1997).","journal-title":"Brain Res."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1523\/JNEUROSCI.22-10-04153.2002","article-title":"Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons","volume":"22","author":"Akbarian S.","year":"2002","unstructured":"S. Akbarian, M. Rios, R. J. Liu, S. J. Gold, H. F. Fong, S. Zeiler, V. Coppola, L. Tessarollo, K. R. Jones, E. J. Nestler, G. K. Aghajanian, R. Jaenisch, Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons. J. Neurosci. 22, 4153\u20134162 (2002).","journal-title":"J. Neurosci."},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/FBP.0b013e32834aff54","article-title":"Some determinants of morphine effects on intracranial self-stimulation in rats: Dose, pretreatment time, repeated treatment, and rate dependence","volume":"22","author":"Altarifi A. A.","year":"2011","unstructured":"A. A. Altarifi, S. S. Negus, Some determinants of morphine effects on intracranial self-stimulation in rats: Dose, pretreatment time, repeated treatment, and rate dependence. Behav. Pharmacol. 22, 663\u2013673 (2011).","journal-title":"Behav. Pharmacol."},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00213-011-2464-4","article-title":"Dose escalation and dose preference in extended-access heroin self-administration in Lewis and Fischer rats","volume":"220","author":"Picetti R.","year":"2012","unstructured":"R. Picetti, J. A. Caccavo, A. Ho, M. J. Kreek, Dose escalation and dose preference in extended-access heroin self-administration in Lewis and Fischer rats. Psychopharmacology 220, 163\u2013172 (2012).","journal-title":"Psychopharmacology"},{"key":"e_1_3_2_42_2","first-page":"8","article-title":"Molecular cloning and functional expression of a mu-opioid receptor from rat brain","volume":"44","author":"Chen Y.","year":"1993","unstructured":"Y. Chen, A. Mestek, J. Liu, J. A. Hurley, L. Yu, Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol. Pharmacol. 44, 8\u201312 (1993).","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/278423a0","article-title":"Nucleotide sequence of cloned cDNA for bovine corticotropin-\u03b2-lipotropin precursor","volume":"278","author":"Nakanishi S.","year":"1979","unstructured":"S. Nakanishi, A. Inoue, T. Kita, M. Nakamura, A. Chang, S. Cohen, S. Numa, Nucleotide sequence of cloned cDNA for bovine corticotropin-\u03b2-lipotropin precursor. Nature 278, 423\u2013427 (1979).","journal-title":"Nature"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/295206a0","article-title":"Molecular cloning establishes proenkephalin as precursor of enkephalin-containing peptides","volume":"295","author":"Gubler U.","year":"1982","unstructured":"U. Gubler, P. Seeburg, B. J. Hoffman, L. P. Gage, S. Udenfriend, Molecular cloning establishes proenkephalin as precursor of enkephalin-containing peptides. Nature 295, 206\u2013208 (1982).","journal-title":"Nature"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0006-8993(94)90031-0","article-title":"\u03bc-Opioid receptor mRNA expression in the rat CNS: Comparison to mu-receptor binding","volume":"643","author":"Mansour A.","year":"1994","unstructured":"A. Mansour, C. A. Fox, R. C. Thompson, H. Akil, S. J. Watson, \u03bc-Opioid receptor mRNA expression in the rat CNS: Comparison to mu-receptor binding. Brain Res. 643, 245\u2013265 (1994).","journal-title":"Brain Res."},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0169-328X(99)00021-2","article-title":"Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain","volume":"66","author":"Wang X. M.","year":"1999","unstructured":"X. M. Wang, Y. Zhou, R. Spangler, A. Ho, J. S. Han, M. J. Kreek, Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Brain Res. Mol. Brain Res. 66, 184\u2013187 (1999).","journal-title":"Brain Res. Mol. Brain Res."},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/adb.12405","article-title":"Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol","volume":"22","author":"Becker J. A.","year":"2017","unstructured":"J. A. Becker, B. L. Kieffer, J. Le Merrer, Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol. Addict. Biol. 22, 1205\u20131217 (2017).","journal-title":"Addict. Biol."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3306-3"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroscience.2013.10.062","article-title":"Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression","volume":"258","author":"Mayer-Blackwell B.","year":"2014","unstructured":"B. Mayer-Blackwell, S. D. Schlussman, E. R. Butelman, A. Ho, J. Ott, M. J. Kreek, Y. Zhang, Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression. Neuroscience 258, 280\u2013291 (2014).","journal-title":"Neuroscience"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuroscience.2014.11.013","article-title":"Self administration of oxycodone alters synaptic plasticity gene expression in the hippocampus differentially in male adolescent and adult mice","volume":"285","author":"Zhang Y.","year":"2015","unstructured":"Y. Zhang, A. J. Brownstein, M. Buonora, K. Niikura, A. Ho, J. Correa da Rosa, M. J. Kreek, J. Ott, Self administration of oxycodone alters synaptic plasticity gene expression in the hippocampus differentially in male adolescent and adult mice. Neuroscience 285, 34\u201346 (2015).","journal-title":"Neuroscience"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1007\/s00213-017-4657-y","article-title":"Alterations of expression of inflammation\/immune-related genes in the dorsal and ventral striatum of adult C57BL\/6J mice following chronic oxycodone self-administration: A RNA sequencing study","volume":"234","author":"Zhang Y.","year":"2017","unstructured":"Y. Zhang, Y. Liang, O. Levran, M. Randesi, V. Yuferov, C. Zhao, M. J. Kreek, Alterations of expression of inflammation\/immune-related genes in the dorsal and ventral striatum of adult C57BL\/6J mice following chronic oxycodone self-administration: A RNA sequencing study. Psychopharmacology 234, 2259\u20132275 (2017).","journal-title":"Psychopharmacology"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fpsyt.2018.00257","article-title":"Oxycodone self-administration induces alterations in expression of integrin, semaphorin and ephrin genes in the mouse striatum","volume":"9","author":"Yuferov V.","year":"2018","unstructured":"V. Yuferov, Y. Zhang, Y. Liang, C. Zhao, M. Randesi, M. J. Kreek, Oxycodone self-administration induces alterations in expression of integrin, semaphorin and ephrin genes in the mouse striatum. Front. Psych. 9, 257 (2018).","journal-title":"Front. Psych."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2018.07.032"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/archinte.1966.00290160004002","article-title":"Narcotic blockade","volume":"118","author":"Dole V. P.","year":"1966","unstructured":"V. P. Dole, M. E. Nyswander, M. J. Kreek, Narcotic blockade. Arch. Intern. Med. 118, 304\u2013309 (1966).","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.2000.tb06683.x","article-title":"Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine","volume":"909","author":"Kreek M. J.","year":"2000","unstructured":"M. J. Kreek, Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann. N. Y. Acad. Sci. 909, 186\u2013216 (2000).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"e_1_3_2_56_2","unstructured":"M. J. Kreek in Proceedings of the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence L. S. Harris Ed. (NIDA Research Monographs 2000) pp. 3\u201322."},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0740-5472(02)00259-3","article-title":"History and current status of opioid maintenance treatments: Blending conference session","volume":"23","author":"Kreek M. J.","year":"2002","unstructured":"M. J. Kreek, F. J. Vocci, History and current status of opioid maintenance treatments: Blending conference session. J. Subst. Abuse Treat. 23, 93\u2013105 (2002).","journal-title":"J. Subst. Abuse Treat."},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/10826084.2017.1298619","article-title":"Characteristics and outcome of male and female methadone maintenance patients: MMT in Tel Aviv and Las Vegas","volume":"53","author":"Adelson M.","year":"2018","unstructured":"M. Adelson, S. Linzy, E. Peles, Characteristics and outcome of male and female methadone maintenance patients: MMT in Tel Aviv and Las Vegas. Subst. Use Misuse 53, 230\u2013238 (2018).","journal-title":"Subst. Use Misuse"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1824728"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(97)13391-2","article-title":"The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord","volume":"223","author":"Gorman A. L.","year":"1997","unstructured":"A. L. Gorman, K. J. Elliott, C. E. Inturrisi, The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. 223, 5\u20138 (1997).","journal-title":"Neurosci. Lett."},{"key":"e_1_3_2_61_2","first-page":"2773","article-title":"Plasma and urine levels of methadone","volume":"73","author":"Kreek M. J.","year":"1973","unstructured":"M. J. Kreek, Plasma and urine levels of methadone. N. Y. State J. Med. 73, 2773\u20132777 (1973).","journal-title":"N. Y. State J. Med."},{"key":"e_1_3_2_62_2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/jps.2600661120","article-title":"Quantitative analysis of methadone in biological fluids using deuterium-labeled methadone and GLC-chemical-ionization mass spectrometry","volume":"66","author":"Hachey D. L.","year":"1977","unstructured":"D. L. Hachey, M. J. Kreek, D. H. Mattson, Quantitative analysis of methadone in biological fluids using deuterium-labeled methadone and GLC-chemical-ionization mass spectrometry. J. Pharm. Sci. 66, 1579\u20131582 (1977).","journal-title":"J. Pharm. Sci."},{"key":"e_1_3_2_63_2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0024-3205(79)90343-6","article-title":"Stereoselective disposition of methadone in man","volume":"24","author":"Kreek M. J.","year":"1979","unstructured":"M. J. Kreek, D. L. Hachey, P. D. Klein, Stereoselective disposition of methadone in man. Life Sci. 24, 925\u2013932 (1979).","journal-title":"Life Sci."},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jps.2600710110","article-title":"Quantitation of methadone enantiomers in humans using stable isotope-labeled [2H3]-, [2H5]-, and [2H8]Methadone","volume":"71","author":"Nakamura K.","year":"1982","unstructured":"K. Nakamura, D. L. Hachey, M. J. Kreek, C. S. Irving, P. D. Klein, Quantitation of methadone enantiomers in humans using stable isotope-labeled [2H3]-, [2H5]-, and [2H8]Methadone. J. Pharm. Sci. 71, 40\u201343 (1982).","journal-title":"J. Pharm. Sci."},{"key":"e_1_3_2_65_2","first-page":"1070","article-title":"Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts","volume":"295","author":"Kling M. A.","year":"2000","unstructured":"M. A. Kling, R. E. Carson, L. Borg, A. Zametkin, J. A. Matochik, J. Schluger, P. Herscovitch, K. C. Rice, A. Ho, W. C. Eckelman, M. J. Kreek, Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J. Pharmacol. Exp. Ther. 295, 1070\u20131076 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_66_2","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0376-8716(03)00057-7","article-title":"Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment?","volume":"70","author":"Mendelson J.","year":"2003","unstructured":"J. Mendelson, R. T. Jones, Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? Drug Alcohol Depend. 70, S29\u2013S37 (2003).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_2_67_2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight B. R.","year":"2019","unstructured":"B. R. Haight, S. M. Learned, C. M. Laffont, P. J. Fudala, Y. Zhao, A. S. Garofalo, M. K. Greenwald, V. R. Nadipelli, W. Ling, C. Heidbreder, Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 393, 778\u2013790 (2019).","journal-title":"Lancet"},{"key":"e_1_3_2_68_2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial","volume":"361","author":"Kakko J.","year":"2003","unstructured":"J. Kakko, K. D. Svanborg, M. J. Kreek, M. Heilig, 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 361, 662\u2013668 (2003).","journal-title":"Lancet"},{"key":"e_1_3_2_69_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy","volume":"144","author":"Greenwald M. K.","year":"2014","unstructured":"M. K. Greenwald, S. D. Comer, D. A. Fiellin, Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy. Drug Alcohol Depend. 144, 1\u201311 (2014).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2006.01.022","article-title":"Reversibility of opioid receptor occupancy of buprenorphine in vivo","volume":"534","author":"Englberger W.","year":"2006","unstructured":"W. Englberger, B. K\u00f6gel, E. Friderichs, W. Strassburger, T. Germann, Reversibility of opioid receptor occupancy of buprenorphine in vivo. Eur. J. Pharmacol. 534, 95\u2013102 (2006).","journal-title":"Eur. J. Pharmacol."},{"key":"e_1_3_2_71_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/pr.112.005942","article-title":"Regulation of\u03bc-opioid receptors: Desensitization, phosphorylation, internalization, and tolerance","volume":"65","author":"Williams J. T.","year":"2013","unstructured":"J. T. Williams, S. L. Ingram, G. Henderson, C. Chavkin, M. von Zastrow, S. Schulz, T. Koch, C. J. Evans, M. J. Christie, Regulation of\u03bc-opioid receptors: Desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223\u2013254 (2013).","journal-title":"Pharmacol. Rev."},{"key":"e_1_3_2_72_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(11)61330-5","article-title":"Injectable extended-release naltrexone for opioid dependence","volume":"378","author":"Woody G. E.","year":"2011","unstructured":"G. E. Woody, D. S. Metzger, Injectable extended-release naltrexone for opioid dependence. Lancet 378, 664\u2013665 (2011).","journal-title":"Lancet"},{"key":"e_1_3_2_73_2","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.bmcl.2009.02.078","article-title":"Syntheses of novel high affinity ligands for opioid receptors","volume":"19","author":"Wentland M. P.","year":"2009","unstructured":"M. P. Wentland, R. Lou, Q. Lu, Y. Bu, C. Denhardt, J. Jin, R. Ganorkar, M. A. VanAlstine, C. Guo, D. J. Cohen, J. M. Bidlack, Syntheses of novel high affinity ligands for opioid receptors. Bioorg. Med. Chem. Lett. 19, 2289\u20132294 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"e_1_3_2_74_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee J. D.","year":"2017","unstructured":"J. D. Lee, E. V. Nunes Jr., P. Novo, K. Bachrach, G. L. Bailey, S. Bhatt, S. Farkas, M. Fishman, P. Gauthier, C. C. Hodgkins, J. King, R. Lindblad, D. Liu, A. G. Matthews, J. May, K. M. Peavy, S. Ross, D. Salazar, P. Schkolnik, D. Shmueli-Blumberg, D. Stablein, G. Subramaniam, J. Rotrosen, Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. Lancet 391, 309\u2013318 (2017).","journal-title":"Lancet"},{"key":"e_1_3_2_75_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11920-010-0135-5","article-title":"Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available","volume":"12","author":"Krupitsky E.","year":"2010","unstructured":"E. Krupitsky, E. Zvartau, G. Woody, Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr. Psychiatry Rep. 12, 448\u2013453 (2010).","journal-title":"Curr. Psychiatry Rep."},{"key":"e_1_3_2_76_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial","volume":"63","author":"Comer S. D.","year":"2006","unstructured":"S. D. Comer, M. A. Sullivan, E. Yu, J. L. Rothenberg, H. D. Kleber, K. Kampman, C. Dackis, C. P. O'Brien, Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch. Gen. Psychiatry 63, 210\u2013218 (2006).","journal-title":"Arch. Gen. Psychiatry"},{"key":"e_1_3_2_77_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002130100909","article-title":"Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans","volume":"159","author":"Comer S. D.","year":"2002","unstructured":"S. D. Comer, E. D. Collins, H. D. Kleber, E. S. Nuwayser, J. H. Kerrigan, M. W. Fischman, Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 159, 351\u2013360 (2002).","journal-title":"Psychopharmacology"},{"key":"e_1_3_2_78_2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuropharm.2015.08.032","article-title":"Noribogaine is a G-protein biased \u03ba-opioid receptor agonist","volume":"99","author":"Maillet E. L.","year":"2015","unstructured":"E. L. Maillet, N. Milon, M. D. Heghinian, J. Fishback, S. C. Schurer, N. Garamszegi, D. C. Mash, Noribogaine is a G-protein biased \u03ba-opioid receptor agonist. Neuropharmacology 99, 675\u2013688 (2015).","journal-title":"Neuropharmacology"},{"key":"e_1_3_2_79_2","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity?","volume":"30","author":"Bart G.","year":"2005","unstructured":"G. Bart, J. H. Schluger, L. Borg, A. Ho, J. M. Bidlack, M. J. Kreek, Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity? Neuropsychopharmacology 30, 2254\u20132262 (2005).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_80_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: A deadly new trend","volume":"11","author":"Prekupec M. P.","year":"2017","unstructured":"M. P. Prekupec, P. A. Mansky, M. H. Baumann, Misuse of novel synthetic opioids: A deadly new trend. J. Addict. Med. 11, 256\u2013265 (2017).","journal-title":"J. Addict. Med."},{"key":"e_1_3_2_81_2","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.118.256115","article-title":"Fighting fire with fire: Development of intranasal nalmefene to treat synthetic opioid overdose","author":"Krieter P.","year":"2019","unstructured":"P. Krieter, S. Gyaw, R. Crystal, P. Skolnick, Fighting fire with fire: Development of intranasal nalmefene to treat synthetic opioid overdose. J. Pharmacol. Exp. Ther. jpet.118.256115, (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"e_1_3_2_82_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0024-3205(83)90529-5","article-title":"Circadian rhythms and levels of \u03b2-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans","volume":"33","author":"Kreek M. J.","year":"1983","unstructured":"M. J. Kreek, S. L. Wardlaw, N. Hartman, J. Raghunath, J. Friedman, B. Schneider, A. G. Frantz, Circadian rhythms and levels of \u03b2-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 33 (suppl. 1), 409\u2013411 (1983).","journal-title":"Life Sci."},{"key":"e_1_3_2_83_2","first-page":"1970","article-title":"Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin","volume":"74","author":"Cushman P. J.","year":"1974","unstructured":"P. J. Cushman Jr., M. J. Kreek, Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin. N. Y. State J. Med. 74, 1970\u20131973 (1974).","journal-title":"N. Y. State J. Med."},{"key":"e_1_3_2_84_2","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","article-title":"Single-nucleotide polymorphism in the human mu opioid receptor gene alters \u03b2-endorphin binding and activity: Possible implications for opiate addiction","volume":"95","author":"Bond C.","year":"1998","unstructured":"C. Bond, K. S. LaForge, M. Tian, D. Melia, S. Zhang, L. Borg, J. Gong, J. Schluger, J. A. Strong, S. M. Leal, J. A. Tischfield, M. J. Kreek, L. Yu, Single-nucleotide polymorphism in the human mu opioid receptor gene alters \u03b2-endorphin binding and activity: Possible implications for opiate addiction. Proc. Natl. Acad. Sci. U.S.A. 95, 9608\u20139613 (1998).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"e_1_3_2_85_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.mp.4001504","article-title":"Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden","volume":"9","author":"Bart G.","year":"2004","unstructured":"G. Bart, M. Heilig, K. S. LaForge, L. Pollak, S. M. Leal, J. Ott, M. J. Kreek, Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry 9, 547\u2013549 (2004).","journal-title":"Mol. Psychiatry"},{"key":"e_1_3_2_86_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.npp.1300598","article-title":"Increased attributable risk related to a functional \u03bc-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden","volume":"30","author":"Bart G.","year":"2005","unstructured":"G. Bart, M. J. Kreek, J. Ott, K. S. LaForge, D. Proudnikov, L. Pollak, M. Heilig, Increased attributable risk related to a functional \u03bc-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30, 417\u2013422 (2005).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_87_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0893-133X(01)00294-9","article-title":"The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade","volume":"26","author":"Wand G. S.","year":"2002","unstructured":"G. S. Wand, M. McCaul, X. Yang, J. Reynolds, D. Gotjen, S. Lee, A. Ali, The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26, 106\u2013114 (2002).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_88_2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ajmg.b.10054","article-title":"Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the \u03bc-opioid receptor locus (OPRM1)","volume":"118","author":"Hernandez-Avila C. A.","year":"2003","unstructured":"C. A. Hernandez-Avila, G. Wand, X. Luo, J. Gelernter, H. R. Kranzler, Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the \u03bc-opioid receptor locus (OPRM1). Am. J. Med. Genet. B Neuropsychiatr. Genet. 118B, 60\u201365 (2003).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"e_1_3_2_89_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1369-1600.2011.00313.x","article-title":"Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone","volume":"18","author":"Ducat E.","year":"2013","unstructured":"E. Ducat, B. Ray, G. Bart, Y. Umemura, J. Varon, A. Ho, M. J. Kreek, Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. Addict. Biol. 18, 325\u2013331 (2013).","journal-title":"Addict. Biol."},{"key":"e_1_3_2_90_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/npp.2014.286","article-title":"Mouse model of the OPRM1 (A118G) polymorphism: Differential heroin self-administration behavior compared with wild-type mice","volume":"40","author":"Zhang Y.","year":"2015","unstructured":"Y. Zhang, R. Picetti, E. R. Butelman, A. Ho, J. A. Blendy, M. J. Kreek, Mouse model of the OPRM1 (A118G) polymorphism: Differential heroin self-administration behavior compared with wild-type mice. Neuropsychopharmacology 40, 1091\u20131100 (2015).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.copsyc.2018.07.014","article-title":"A review of opioid addiction genetics","volume":"27","author":"Crist R. C.","year":"2018","unstructured":"R. C. Crist, B. C. Reiner, W. H. Berrettini, A review of opioid addiction genetics. Curr. Opin. Psychol. 27, 31\u201335 (2018).","journal-title":"Curr. Opin. Psychol."},{"key":"e_1_3_2_92_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","article-title":"CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction","volume":"18","author":"Levran O.","year":"2013","unstructured":"O. Levran, E. Peles, S. Hamon, M. Randesi, M. Adelson, M. J. Kreek, CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. 18, 709\u2013716 (2013).","journal-title":"Addict. Biol."},{"key":"e_1_3_2_93_2","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","article-title":"ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence","volume":"17","author":"Levran O.","year":"2008","unstructured":"O. Levran, K. O\u2019Hara, E. Peles, D. Li, S. Barral, B. Ray, L. Borg, J. Ott, M. Adelson, M. J. Kreek, ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 17, 2219\u20132227 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"e_1_3_2_94_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.fpc.0000220566.90466.a2","article-title":"The \u03bc-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers","volume":"16","author":"Oertel B. G.","year":"2006","unstructured":"B. G. Oertel, R. Schmidt, A. Schneider, G. Geisslinger, J. L\u00f6tsch, The \u03bc-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet. Genomics 16, 625\u2013636 (2006).","journal-title":"Pharmacogenet. Genomics"},{"key":"e_1_3_2_95_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1369-1600.2010.00248.x","article-title":"Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity","volume":"16","author":"Rouault M.","year":"2011","unstructured":"M. Rouault, D. A. Nielsen, A. Ho, M. J. Kreek, V. Yuferov, Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity. Addict. Biol. 16, 334\u2013346 (2011).","journal-title":"Addict. Biol."},{"key":"e_1_3_2_96_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neulet.2019.03.038","article-title":"Association of variants of prodynorphin promoter 68-bp repeats in Caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use","volume":"704","author":"Yuferov V.","year":"2019","unstructured":"V. Yuferov, M. Randesi, E. R. Butelman, W. van den Brink, P. Blanken, J. M. van Ree, J. Ott, M. J. Kreek, Association of variants of prodynorphin promoter 68-bp repeats in Caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use. Neurosci. Lett. 704, 100\u2013105 (2019).","journal-title":"Neurosci. Lett."},{"key":"e_1_3_2_97_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00041444-200512000-00013","article-title":"A functional prodynorphin promoter polymorphism and opioid dependence","volume":"15","author":"Ray R.","year":"2005","unstructured":"R. Ray, G. A. Doyle, J. J. Crowley, R. J. Buono, D. W. Oslin, A. A. Patkar, P. Mannelli, P. A. DeMaria Jr., C. P. O\u2019Brien, W. H. Berrettini, A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatr. Genet. 15, 295\u2013298 (2005).","journal-title":"Psychiatr. Genet."},{"key":"e_1_3_2_98_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1369-1600.2007.00069.x","article-title":"Prodynorphin gene promoter repeat associated with cocaine\/alcohol codependence","volume":"12","author":"Williams T. J.","year":"2007","unstructured":"T. J. Williams, K. S. LaForge, D. Gordon, G. Bart, S. Kellogg, J. Ott, M. J. Kreek, Prodynorphin gene promoter repeat associated with cocaine\/alcohol codependence. Addict. Biol. 12, 496\u2013502 (2007).","journal-title":"Addict. Biol."},{"key":"e_1_3_2_99_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/ajmg.b.30491","article-title":"The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in Caucasians","volume":"144","author":"Tyndale R. F.","year":"2007","unstructured":"R. F. Tyndale, J. I. Payne, A. L. Gerber, J. C. Sipe, The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in Caucasians. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 660\u2013666 (2007).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"e_1_3_2_100_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/tpj.2009.59","article-title":"Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: Impact of long repeats of CNR1","volume":"10","author":"Proudnikov D.","year":"2010","unstructured":"D. Proudnikov, T. Kroslak, J. C. Sipe, M. Randesi, D. Li, S. Hamon, A. Ho, J. Ott, M. J. Kreek, Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: Impact of long repeats of CNR1. Pharmacogenomics J. 10, 232\u2013242 (2010).","journal-title":"Pharmacogenomics J."},{"key":"e_1_3_2_101_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/YPG.0b013e32833511f6","article-title":"Evidence for association of two variants of the nociceptin\/orphanin FQ receptor gene OPRL1 with vulnerability to develop opiate addiction in Caucasians","volume":"20","author":"Briant J. A.","year":"2010","unstructured":"J. A. Briant, D. A. Nielsen, D. Proudnikov, D. Londono, A. Ho, J. Ott, M. J. Kreek, Evidence for association of two variants of the nociceptin\/orphanin FQ receptor gene OPRL1 with vulnerability to develop opiate addiction in Caucasians. Psychiatr. Genet. 20, 65\u201372 (2010).","journal-title":"Psychiatr. Genet."},{"key":"e_1_3_2_102_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/YPG.0b013e32833a2106","article-title":"Genome-wide association study identifies genes that may contribute to risk for developing heroin addiction","volume":"20","author":"Nielsen D. A.","year":"2010","unstructured":"D. A. Nielsen, F. Ji, V. Yuferov, A. Ho, C. He, J. Ott, M. J. Kreek, Genome-wide association study identifies genes that may contribute to risk for developing heroin addiction. Psychiatr. Genet. 20, 207\u2013214 (2010).","journal-title":"Psychiatr. Genet."},{"key":"e_1_3_2_103_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/jhg.2010.150","article-title":"Haplotype block structure of the genomic region of the mu opioid receptor gene","volume":"56","author":"Levran O.","year":"2011","unstructured":"O. Levran, O. Awolesi, S. Linzy, M. Adelson, M. J. Kreek, Haplotype block structure of the genomic region of the mu opioid receptor gene. J. Hum. Genet. 56, 147\u2013155 (2011).","journal-title":"J. Hum. Genet."},{"key":"e_1_3_2_104_2","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, phase IIb study investigating oliceridine (TRV130), a novel \u03bc-receptor G-protein pathway selective (\u03bc-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty","volume":"10","author":"Singla N.","year":"2017","unstructured":"N. Singla, H. S. Minkowitz, D. G. Soergel, D. A. Burt, R. A. Subach, M. Y. Salamea, M. J. Fossler, F. Skobieranda, A randomized, phase IIb study investigating oliceridine (TRV130), a novel \u03bc-receptor G-protein pathway selective (\u03bc-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J. Pain Res. 10, 2413\u20132424 (2017).","journal-title":"J. Pain Res."},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.035"},{"key":"e_1_3_2_106_2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.tips.2018.08.007","article-title":"Abuse potential of biased mu opioid receptor agonists","volume":"39","author":"Negus S. S.","year":"2018","unstructured":"S. S. Negus, K. B. Freeman, Abuse potential of biased mu opioid receptor agonists. Trends Pharmacol. Sci. 39, 916\u2013919 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"e_1_3_2_107_2","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1038\/s41598-018-27313-4","article-title":"Opioid receptor signaling, analgesic and side effects induced by a computationally designed pH-dependent agonist","volume":"8","author":"Spahn V.","year":"2018","unstructured":"V. Spahn, G. Del Vecchio, A. Rodriguez-Gaztelumendi, J. Temp, D. Labuz, M. Kloner, M. Reidelbach, H. Machelska, M. Weber, C. Stein, Opioid receptor signaling, analgesic and side effects induced by a computationally designed pH-dependent agonist. Sci. Rep. 8, 8965 (2018).","journal-title":"Sci. Rep."},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3483"},{"key":"e_1_3_2_109_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/00325481.2019.1574403","article-title":"Reframing chronic pain as a disease, not a symptom: Rationale and implications for pain management","volume":"131","author":"Clauw D. J.","year":"2019","unstructured":"D. J. Clauw, M. N. Essex, V. Pitman, K. D. Jones, Reframing chronic pain as a disease, not a symptom: Rationale and implications for pain management. Postgrad. Med. 131, 185\u2013198 (2019).","journal-title":"Postgrad. Med."},{"key":"e_1_3_2_110_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2012.05.005","article-title":"\u03ba-opioid receptor\/dynorphin system: Genetic and pharmacotherapeutic implications for addiction","volume":"35","author":"Butelman E. R.","year":"2012","unstructured":"E. R. Butelman, V. Yuferov, M. J. Kreek, \u03ba-opioid receptor\/dynorphin system: Genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 35, 587\u2013596 (2012).","journal-title":"Trends Neurosci."},{"key":"e_1_3_2_111_2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ijnp\/pyy034","article-title":"Structurally-related kappa opioid receptor agonists with substantial differential signaling bias: Neuroendocrine and behavioral effects in C57BL6 mice","volume":"21","author":"Dunn A. D.","year":"2018","unstructured":"A. D. Dunn, B. Reed, C. Guariglia, A. M. Dunn, J. M. Hillman, M. J. Kreek, Structurally-related kappa opioid receptor agonists with substantial differential signaling bias: Neuroendocrine and behavioral effects in C57BL6 mice. Int. J. Neuropsychopharmacol. 21, 847\u2013857 (2018).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"e_1_3_2_112_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/npp.2017.205","article-title":"Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence","volume":"43","author":"Reed B.","year":"2017","unstructured":"B. Reed, E. R. Butelman, R. Fry, R. Kimani, M. J. Kreek, Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence. Neuropsychopharmacology 43, 739\u2013750 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_113_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0893-133X(00)00222-0","article-title":"Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction","volume":"24","author":"Schluger J. H.","year":"2001","unstructured":"J. H. Schluger, L. Borg, A. Ho, M. J. Kreek, Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology 24, 568\u2013575 (2001).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_114_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.tips.2010.04.003","article-title":"Neuropathic and chronic pain stimuli downregulate central \u03bc-opioid and dopaminergic transmission","volume":"31","author":"Niikura K.","year":"2010","unstructured":"K. Niikura, M. Narita, E. R. Butelman, M. J. Kreek, T. Suzuki, Neuropathic and chronic pain stimuli downregulate central \u03bc-opioid and dopaminergic transmission. Trends Pharmacol. Sci. 31, 299\u2013305 (2010).","journal-title":"Trends Pharmacol. Sci."},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.02.029"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0293-z"},{"key":"e_1_3_2_117_2","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1056\/NEJM198405103101902","article-title":"The pharmacokinetics of heroin in patients with chronic pain","volume":"310","author":"Inturrisi C. E.","year":"1984","unstructured":"C. E. Inturrisi, M. B. Max, K. M. Foley, M. Schultz, S.-U. Shin, R. W. Houde, The pharmacokinetics of heroin in patients with chronic pain. N. Engl. J. Med. 310, 1213\u20131217 (1984).","journal-title":"N. Engl. J. Med."}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.aax9140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:25:27Z","timestamp":1704803127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.aax9140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,11]]}},"alternative-id":["10.1126\/sciadv.aax9140"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.aax9140","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"article-number":"eaax9140"}}